Amylin & The Future of Metabolic Medicine

Amylin, the partner hormone co-secreted with insulin, has long been underappreciated in metabolic medicine. This ebook explores its powerful roles in appetite regulation, gastric emptying, glucagon control, and energy balance—and why next-generation amylin-based therapies are poised to transform care for obesity, type 2 diabetes, and related metabolic conditions.

From the science of amylin receptors to the latest clinical advances in long-acting analogs, dual and multi-agonists (including combinations with GLP-1 therapies), and emerging treatment strategies, the book offers a clear, evidence-based roadmap. It examines how these innovations may deliver meaningful weight loss, improved glycemic control, better tolerability for some patients, and new options beyond current incretin therapies.

Written for clinicians, health professionals, and informed readers navigating the rapidly evolving landscape of metabolic medicine, Amylin & The Future of Metabolic Medicine provides practical insights into the mechanisms, pipeline developments, clinical implications, and the potential of restoring more physiological satiety and metabolic signaling.